Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin.
In a pilot study 16 patients with advanced inoperable stomach cancer were treated with Etoposide, Adriamycin, Cisplatin. The recommended dose for phase II studies was established and first therapy results are presented. Two of 16 patients responded with complete remissions and 8 with partial remissions. The recommended dose schedule for phase II studies is: Adriamycin 20 mg/m2 i.v. day 1 + 7; Cisplatin 40 mg/m2 i.v. day 2 + 8; Etoposide 120 mg/m2 i.v. day 4, 5, 6, every four weeks.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery
D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin